ArticleClinicoEconomics and outcomes research : CEOR2021

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.

Anshul Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.